14678-86-5

Basic information

• Product Name: 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
• Synonyms: 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester;5-Amino-1-(2-chloro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester HCl Salt;Ethyl 5-amino-1-(2-chlorophenyl)
• CAS NO: 14678-86-5
• Molecular Formula: C₁₂H₁₂ClN₃O₂
• Molecular Weight: 265.69558
• Mol File: 14678-86-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: 83-84℃
• Boiling Point: 415.9 °C at 760 mmHg
• Flash Point: 205.3 °C
• Appearance: /
• Density: 1.37
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.45±0.13(Predicted)
• CAS DataBase Reference: 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester(14678-86-5)
• EPA Substance Registry System: 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester(14678-86-5)

Safety Data

• Hazardous Substances Data: 14678-86-5(Hazardous Substances Data)

Usage

General Description

5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester is a chemical compound with a molecular formula C11H11ClN4O2. It is an ethyl ester derivative of 5-amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid and belongs to the class of pyrazole carboxylic acid esters. 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester is used in pharmaceutical research as a building block for the synthesis of various biologically active molecules. Its potential applications include drug discovery and development for the treatment of various diseases and medical conditions. Additionally, its unique structural features make it a valuable tool in the study of the structure-activity relationships of related compounds.

Upstream product

• 41052-75-9 o-chlorophenylhydrazine hydrochloride 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 10449-07-7 (2-chlorophenyl)hydrazine 

Downstream Products

• 1345714-06-8 C₂₂H₂₅ClN₄O₃S 

Relevant articles and documents

Targeting Pim Kinases and DAPK3 to Control Hypertension

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.